We are live on ! Find out more
SPRB

Spruce Biosciences
SPRB

31 hedge funds and large institutions have $3.03M invested in Spruce Biosciences in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 31 → 31 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

35% less capital invested

Capital invested by funds: $4.69M → $3.03M (-$1.66M)

Holders
31
Holders Change
–
Holders Change %
0%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$17.7K
2
VF
Virtu Financial
New York
+$14.7K
3
Jane Street
Jane Street
New York
+$13.9K
4
UBS Group
UBS Group
Switzerland
+$11.3K
5
GSC
Ground Swell Capital
South Carolina
+$6.44K

Top Sellers

Rank Fund Capital Flow
1
SCV
Sands Capital Ventures
Virginia
-$301K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$24.8K
3
Northern Trust
Northern Trust
Illinois
-$17.7K
4
HF
HRT Financial
New York
-$15K
5
BCM
Bridgeway Capital Management
Texas
-$14.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
1
Carlyle Group
District of Columbia
$840K – – –
RSCM
2
Rock Springs Capital Management
Maryland
$757K – – –
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$301K – – –
IC
4
Ikarian Capital
Texas
$290K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$245K – – –
ACM
6
ADAR1 Capital Management
Texas
$117K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$111K -$8.55K -307 -6%
BFM
8
Boothbay Fund Management
New York
$83.8K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$80.3K +$1.09K +39 +1%
BlackRock
10
BlackRock
New York
$36.2K – – –
UBS Group
11
UBS Group
Switzerland
$33.8K +$11.3K +406 +35%
LPC
12
Lion Point Capital
New York
$21.8K – – –
State Street
13
State Street
Massachusetts
$17.6K – – –
TSS
14
Two Sigma Securities
New York
$13.8K +$17.7K +636 New
XT
15
XTX Topco
Cayman Islands
$12K +$2.12K +76 +16%
SC
16
Shay Capital
New York
$11.1K – – –
VF
17
Virtu Financial
New York
$11K +$14.7K +526 New
Jane Street
18
Jane Street
New York
$10.9K +$13.9K +499 New
Northern Trust
19
Northern Trust
Illinois
$9.49K -$17.7K -635 -59%
Two Sigma Investments
20
Two Sigma Investments
New York
$5.96K -$28 -1 -0.4%
GSC
21
Ground Swell Capital
South Carolina
$5.02K +$6.44K +231 New
MG
22
Marex Group
$4.29K – – –
Two Sigma Advisers
23
Two Sigma Advisers
New York
$3.54K -$585 -21 -11%
Citigroup
24
Citigroup
New York
$3.21K +$4.12K +148 New
Morgan Stanley
25
Morgan Stanley
New York
$2.15K +$1.98K +71 +254%
1
2

SPRB Hedge Fund Activity: Q1 2025 in Review

31 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q1 2025, worth a combined $3.03M — down 35% from $4.69M a quarter earlier.

Fund positioning in SPRB was balanced in Q1 2025: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 5 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $17.7K. The largest seller was Sands Capital Ventures, exiting entirely with an estimated $301K sold.

  • 31 institutional investors held Spruce Biosciences (SPRB) as of Q1 2025, unchanged from Q4 2024.
  • Funds reported $3.03M of Spruce Biosciences stock for Q1 2025, down 35% quarter-over-quarter.
  • 5 funds opened new Spruce Biosciences positions in Q1 2025 and 5 closed out, a net change of 0 holders.
  • The largest Spruce Biosciences buyer in Q1 2025 was Two Sigma Securities, an estimated $17.7K added.
  • The largest Spruce Biosciences seller in Q1 2025 was Sands Capital Ventures, an estimated $301K sold.

Based on aggregated 13F filings for Q1 2025.